|Institutional Source||Beutler Lab|
|Gene Name||solute carrier family 6 (neurotransmitter transporter, dopamine), member 3|
|Is this an essential gene?||Non essential (E-score: 0.000)|
|Stock #||R5355 (G1)|
|Chromosomal Location||73536747-73578672 bp(+) (GRCm38)|
|Type of Mutation||missense|
|DNA Base Change (assembly)||A to G at 73560959 bp|
|Amino Acid Change||Tyrosine to Cysteine at position 334 (Y334C)|
|Ref Sequence||ENSEMBL: ENSMUSP00000022100 (fasta)|
|Gene Model||predicted gene model for transcript(s): [ENSMUST00000022100]|
|Predicted Effect||probably damaging
AA Change: Y334C
PolyPhen 2 Score 1.000 (Sensitivity: 0.00; Specificity: 1.00)
AA Change: Y334C
|Meta Mutation Damage Score||0.9507|
|Coding Region Coverage||
|Validation Efficiency||94% (50/53)|
FUNCTION: [Summary is not available for the mouse gene. This summary is for the human ortholog.] This gene encodes a dopamine transporter which is a member of the sodium- and chloride-dependent neurotransmitter transporter family. The 3' UTR of this gene contains a 40 bp tandem repeat, referred to as a variable number tandem repeat or VNTR, which can be present in 3 to 11 copies. Variation in the number of repeats is associated with idiopathic epilepsy, attention-deficit hyperactivity disorder, dependence on alcohol and cocaine, susceptibility to Parkinson disease and protection against nicotine dependence.[provided by RefSeq, Nov 2009]
PHENOTYPE: Homozygotes for targeted null mutations exhibit dwarfism, hyperactivity (especially in a novel environment), 5-fold higher extracellular dopamine levels, impaired spatial cognitive function, anterior pituitary hypoplasia, and failure to lactate. [provided by MGI curators]
|Allele List at MGI|
|Other mutations in this stock||
|Other mutations in Slc6a3||
(F):5'- TGACAGCTCCCATTCTCGAC -3'
(R):5'- TTCAGTGCAAAGCCAAGCC -3'
(F):5'- ACCTCGGGTGGAACTAACTC -3'
(R):5'- ACTTAGGTTGTAGCATGAGACCC -3'